For more than 100 years Grifols has looked to the future, committed to continued, sustainable and ethical growth. We are convinced that only a job well-done, with integrity, rigor and honesty, will allow us to truly create value for patients and society beyond financial performance.
2024 Integrated and Sustainability Annual Report
2023 Executive Summary – Integrated & Sustainability Annual Report
2023 Human Rights Due Diligence Report
2023 Risk and Opportunities Management Related to Climate Change
Modern Slavery & Supply Chain Transparency Statement 2023
Our sustainability efforts are internationally recognized
Grifols ranked number one biotech company in the Dow Jones Best-in-Class Indices (formerly known as DJSI) in its fifth straight year of inclusion in these prestigious indices. This recognition comes as the company achieved its highest-ever S&P Global Corporate Sustainability Assessment (CSA) score, with a rating of 70 points.
Grifols has been awarded a Gold Medal by EcoVadis for the second consecutive year. Achieving a score of 77, ranking among the top 5%, confirms our commitment to sustainability and our position as a leading company in this area.
Grifols participates annually in the Carbon Disclosure Project (CDP), a program that evaluates corporate strategies and performance on climate change and water security.
Grifols has obtained the Prime badge in the ISS ESG corporate rating, which places us as a leading company in our peer industry group.
Grifols is one of the best rated companies by Sustainalytics for our low ESG risk rating.
Since 2018, Grifols has been a constituent of the FTSE4Good Index which identifies companies that demonstrate strong ESG practices measured according to globally recognized standards.
In 2024, Grifols received a BBB rating in the MSCI ESG Ratings assessment.
Codes and Policies
Review our codes of conduct, corporate policies.
Internal Codes & Regulations
Corporate Policies
Historical annual reports
2023
2022
2021
2020
2019
2018
Annual report 2017
Annual report 2016